Low disease activity more difficult to achieve in vulnerable populations. All rheumatic diseases - #RA #PsA #AS initiating DMARDs takes longer in these population #EULAR2025 @RheumNow https://t.co/voIivshKRt

• https://x.com/bella_mehta/status/1933839837376766180/photo/1

RCT in axSpA (N=200): Digital therapeutic Axia added to stable treatment led to significant improvements in BASDAI (–1.66), BASFI (–1.12), ASQoL (–2.51), with ASAS20/40 responses of 51%/23% vs 9%/3% for usual care. Supports role of DTx in axSpA care. Abstract LB0002 @RheumNow https://t.co/oF6bjIwNIY

• https://x.com/synovialjoints/status/1933846906548928914/photo/1
• https://x.com/synovialjoints/status/1933846906548928914/photo/1

NMA of 14RCTs (>2500 pts) eval relative efficacy of bDMARDs and tsDMARDs in mostly biologic naïve nr-axSpA pts. -All therapies studied significantly improved ASAS40 response rates compared to placebo. -Certolizumab and Golimumab were the most effective therapies, followed by https://t.co/BJLRpEDYrv

• https://x.com/AdelaCastro222/status/1933581707665682518/photo/1
• https://x.com/AdelaCastro222/status/1933581707665682518/photo/1

👁️Uveitis in axSpA: -Up to 40% can present before SpA dx -NMA of 44 RCTs showed tx with TNFi, JAKi and IL-17i protective effects against uveitis -Low rates of uveitis in axSpA pts on BIME trials suggests its possible beneficial effects. #EULAR2025 @RheumNow https://t.co/mPuSMnD1Zs

• https://x.com/AdelaCastro222/status/1933583328973894062/photo/1
• https://x.com/AdelaCastro222/status/1933583328973894062/photo/1

In 30 axSpA pts (mean age 42 yrs, BASDAI 3.5, BASFI 2.8, BASMI 2.0, chest expansion 4.5 cm), an 8-wk individualized exercise (cardiorespiratory + trunk strength via cardiopulmonary exercise testing [CPET] & David Back Concept [DBC] devices) ↓ trunk strength deficit 14.1% & https://t.co/505cCEOzu1

• https://x.com/synovialjoints/status/1933596675467075873/photo/1

In 631 axSpA pts (mean age 33y, 54% female) from DESIR cohort, high-dose NSAID use (ASAS NSAID index ≥50) not associated with incident hypertension (HR 1.01; 95% CI 0.98–1.02) over 72 months. NSAID anti-inflammatory effect may offset BP risk in axSpA. Abstract#POS0256 @RheumNow https://t.co/ELYWoJDyKJ

• https://x.com/synovialjoints/status/1933597498548904144/photo/1

In 4,121 SpA pts (mean age 45y; 61% male), composite scores w/ joint counts (DAPSA, DAS28, DAS44) best discriminated peripheral arthritis activity vs PGA & SJC alone. All scores had excellent construct validity; CRP weakest. Composite indices may optimize SpA assessment. https://t.co/oM97BEkkH5

• https://x.com/synovialjoints/status/1933598772090843637/photo/1

In phase II/III trial (NCT04481139), ivarmacitinib 4mg significantly improved PROs in active ankylosing spondylitis: total back pain VAS (-25.6 vs -17.0), night pain (-25.0 vs -14.3), stiffness (-24.5 vs -15.8), PtGA (-23.8 vs -13.3), ASQoL (-3.2 vs -2.4). Benefits seen even https://t.co/RcJ5vfdoHf

• https://x.com/synovialjoints/status/1933601145982722293/photo/1
• https://x.com/synovialjoints/status/1933601145982722293/photo/1

In clinical practice, not all US enthesitis findings are SpA-specific. Enthesophytes/calcifications common in healthy pts. Inflammatory lesions (PD signal, erosions) at Achilles, distal patella & greater trochanter better distinguish PsA/axSpA. Target key sites to improve US https://t.co/jO61QjKfQp

• https://x.com/synovialjoints/status/1933602240897691962/photo/1

In 581 PsA pts (EuroSpA), MRI showed axial SpA features in 31%: BME (69%), erosions (68%), fat lesions (58%). MRI-axPsA pts: younger (41y vs 46y), male (70%), HLA-B27+ (55%), ↑CRP (13 vs 7 mg/L). Radiographs identified sacroiliitis in 29%. MRI adds key detection. POS0297 https://t.co/nAw0BDAH22

• https://x.com/synovialjoints/status/1933603978006475090/photo/1

In real-world PsA, IL-23 inhibitors (guselkumab/risankizumab) showed clinical response in axial/mixed PsA. Best response seen in pts meeting ASAS axial SpA criteria (RR 7.64) & baseline ASDAS-CRP >2.1. Supports role of patient stratification in axial PsA. Abstract#POS0113 https://t.co/qowZZmJOpM

• https://x.com/synovialjoints/status/1933528974468272315/photo/1

Efficacy and Safety of Xeligekimab in AS Dr. Adela Castro reports on abstract OP0102 at the EULAR 2025 meeting in Barcelona, Spain https://t.co/xpzeV0oZOr https://t.co/wmTnFbFcum

• https://buff.ly/jOLBrQY

Are we missing axial/SIJ lesions in PsA or are we misdiagnosing AxSPA + PSO pts for PsA? 5 register studies including 580+ pts w/ PsA/AxSPA+PSO 1/3 PsA routine care patients had SIJ MRI = SPA 29% Rx SII r-mNY criteria+ of which 38% MRI lesions AxSPA @RheumNow #EULAR2025 https://t.co/DJljlm7T9m

• https://x.com/AurelieRheumo/status/1933516733152641267/photo/1